Imosec (Loperamide Hydrochloride)

Loperamide acts as a peripheral μ‑opioid receptor agonist in the intestinal wall. By binding to these receptors it inhibits acetylcholine release, which reduces smooth‑muscle contractions and slows intestinal transit. The prolonged transit allows more water to be reabsorbed, resulting in firmer stools and fewer bowel movements.

The appropriate dose of Imosec is determined by a qualified healthcare professional based on the individual’s condition, severity of symptoms, and response to therapy. Patients should follow the prescriber’s instructions and the product labeling for dosing guidance.

Imosec is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation only if the potential benefit justifies the potential risk, and after consultation with a healthcare provider.

To order Imosec, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Imosec (loperamide) is a peripheral opioid antidiarrheal, distinct from adsorbent agents such as bismuth subsalicylate or antisecretory drugs like racecadotril. It provides rapid symptom relief by slowing gut motility, whereas other classes may work by binding toxins or reducing intestinal secretion. Choice of therapy depends on the underlying cause, patient tolerance and clinical guidelines.

Imosec should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme heat. Keep it out of reach of children and do not use after the expiry date printed on the label.

Imosec is taken orally, usually as a tablet or capsule, with or without water. The exact form and strength are specified on the product label. Patients should swallow the tablet whole and follow the prescriber’s instructions regarding timing relative to meals.

Serious risks include severe constipation that can lead to intestinal obstruction, toxic megacolon, and cardiac arrhythmias such as QT prolongation, especially when combined with CYP3A4 inhibitors or other QT‑prolonging drugs. Any signs of abdominal pain, bloating, or irregular heartbeat should prompt immediate medical evaluation.

Imosec should be avoided in children younger than 2 years, in patients with known hypersensitivity to loperamide, and in individuals with diarrhea caused by invasive bacterial infections or Clostridioides difficile, as slowing gut motility may worsen the condition. Caution is also advised in severe hepatic impairment.